TLA, Targeted Immunotherapies AB
1 clinical trials · Sponsor
◉ Watch TLA, Targeted Immunotherapies AB
| Record | Firm | Date |
|---|---|---|
| Dose-Evaluation Study of the Efficacy and Safety of TLA Gut™ Leukapheresis Treatment in Patients With Ulcerative Colitis (NCT04550130) | TLA, Targeted Immunotherapies AB | 2022-12-01 |
Track TLA, Targeted Immunotherapies AB automatically
Every clearance here is in the API, with alerts when new ones post.